Equities

Biomerica Inc

BMRA:NAQ

Biomerica Inc

Actions
Health CareMedical Equipment and Services
  • Price (USD)0.5806
  • Today's Change-0.049 / -7.84%
  • Shares traded82.98k
  • 1 Year change-57.62%
  • Beta-0.9769
Data delayed at least 15 minutes, as of May 31 2024 21:00 BST.
More ▼
Improved Notifications for Markets Data Alerts
Improved Notifications for Markets Data Alerts
Want push notifications sent directly to your devices for equity price changes and breaking news stories? Let us know here.
 
Existing alertsView our existing alerts
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Biomerica, Inc. is a biomedical technology company. The Company develops, patents, manufactures and markets advanced diagnostic and therapeutic products used at the point-of-care (in home and in physicians’ offices) and in hospital/clinical laboratories for detection and/or treatment of medical conditions and diseases. It is also engaged in the research, development, commercialization and in certain cases regulatory approval, of patented, diagnostic-guided therapy (DGT) products to treat gastrointestinal diseases, such as irritable bowel syndrome (IBS), and other inflammatory diseases. The Company's InFoods IBS product uses a simple blood sample and is designed to identify patient-specific foods that, when removed from the diet, may alleviate IBS symptoms such as pain, bloating, diarrhea and constipation. The Company’s two subsidiaries, Biomerica de Mexico, which is used for assembly/manufacturing and BioEurope GmbH, which acts as a distributor of Biomerica products in certain markets.

  • Revenue in USD (TTM)5.41m
  • Net income in USD-6.35m
  • Incorporated1971
  • Employees62.00
  • Location
    Biomerica Inc17571 VON KARMAN AVENUEIRVINE 92614United StatesUSA
  • Phone+1 (949) 379-2875
  • Fax+1 (949) 553-1231
  • Websitehttps://biomerica.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Predictive Oncology Inc1.96m-14.78m5.87m34.00--1.43--2.99-3.66-3.660.48530.99770.10991.714.9557,642.65-82.89-91.80-108.54-126.2964.1864.64-754.19-1,419.991.35--0.0093--18.244.7545.67--5.44--
Encision Inc6.87m-448.00k5.88m31.00--2.68--0.857-0.0381-0.03810.58350.18631.641.967.84221,520.00-10.69-1.07-14.05-1.4650.5452.27-6.52-0.6131.08-6.220.1123---4.17-3.44-393.90--12.89--
ReShape Lifesciences Inc8.34m-10.92m5.98m31.00--1.32--0.7174-2.30-2.300.73190.19330.67810.81784.52268,871.00-88.83-136.06-162.20-194.3265.8556.30-130.99-408.361.26--0.00---22.79-0.947475.36---49.29--
Sharps Technology Inc0.00-8.71m5.99m3.00--0.8726-----0.6204-0.62040.000.43780.00-------74.67---95.84----------0.492--0.00-------112.12------
Sonendo Inc40.19m-57.74m6.05m216.00--0.2464--0.1504-0.6125-0.55520.4260.34820.44482.077.58186,055.60-63.91---78.82--27.64---143.67--2.14-10.830.4695--5.30---6.78------
Fuse Medical Inc18.40m3.63m6.06m31.002.28--1.640.32950.0360.0360.2307-0.00310.95930.70185.75593,671.9018.910.750448.451.3564.9554.9819.720.65520.3143-1.131.12---8.67-6.72295.1134.66----
Sigyn Therapeutics Inc0.00-3.56m6.43m5.00---------3.04-3.040.00-3.280.00----0.00-724.37-493.15-----------10,223.960.0199-1.92---------41.51------
Vivos Therapeutics Inc13.36m-15.64m6.74m114.00--9.81--0.5048-11.00-11.008.730.21310.9247--31.59117,219.30-108.24-89.72-243.30-149.7058.9070.20-117.06-113.15----0.00---13.8729.4843.04---8.48--
Neurometrix Inc5.27m-7.98m7.70m26.00--0.4058--1.46-6.32-6.324.209.440.23811.2510.08202,700.40-36.07-23.24-38.94-27.2661.9759.17-151.51-48.8810.11--0.00---28.52-18.18-47.84--5.03--
Citrine Global Corp0.00-2.38m9.66m18.00---------0.0025-0.00250.00-0.00280.00----0.00-173.12-298.98---964.26-------4,814.84---5.41--------41.43---5.44--
Biomerica Inc5.41m-6.35m9.77m62.00--1.25--1.81-0.3789-0.37890.32240.46420.58272.285.7487,180.80-68.45-43.55-83.73-50.3211.4115.75-117.46-55.863.37--0.00---71.71-0.8229-57.58---9.76--
PetVivo Holdings Inc1.05m-10.63m10.75m25.00--10.50--10.27-0.8694-0.86940.08420.060.33751.212.0441,841.60-343.12-209.90-715.73-504.6451.4120.27-1,016.55-2,297.210.6169-2,268.840.1392--693.46260.32-73.83--51.73--
Biotricity Inc11.63m-15.39m12.19m55.00------1.05-1.75-1.751.32-2.841.922.016.55211,408.70-240.40-303.46----65.5253.00-125.43-368.780.1012-0.5855----26.00--35.36------
STRATA Skin Sciences Inc32.55m-11.36m13.02m99.00--1.38--0.4001-0.3248-0.32480.93070.2690.733.678.60328,737.40-25.49-11.48-35.77-16.5552.7161.28-34.91-17.700.8376-3.900.6151---7.752.24-95.17--23.29--
ALR Technologies Inc9.49k-8.00m13.18m6.00------1,388.79-0.0147-0.01470.00002-0.04760.0358----1,581.67-3,015.28-12,861.64----62.49---84,283.24-406,011.30---0.8626---------42.72------
Data as of May 31 2024. Currency figures normalised to Biomerica Inc's reporting currency: US Dollar USD

Institutional shareholders

21.03%Per cent of shares held by top holders
HolderShares% Held
Granahan Investment Management, LLCas of 31 Mar 20241.13m6.72%
Wasatch Advisors LPas of 31 Mar 2024953.26k5.67%
The Vanguard Group, Inc.as of 31 Mar 2024609.37k3.62%
Russell Investment Management LLCas of 31 Mar 2024225.44k1.34%
Potomac Capital Management, Inc.as of 31 Dec 2023167.70k1.00%
BlackRock Fund Advisorsas of 31 Mar 2024149.08k0.89%
Geode Capital Management LLCas of 31 Mar 2024126.51k0.75%
G1 Execution Services LLCas of 31 Mar 202465.44k0.39%
Fore Capital LLCas of 31 Mar 202459.68k0.36%
Boothbay Fund Management LLCas of 31 Mar 202451.89k0.31%
More ▼
Data from 31 Dec 2023 - 31 Mar 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.